PROMIS Neurosciences Raises $30.3M for Alzheimer's Trial
By ATTN Desk · Editorial oversight: Sean Han
PROMIS Neurosciences Inc. Overview
PROMIS Neurosciences Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company founded in 2015, with headquarters in Toronto, Ontario, and a research office in Cambridge, Massachusetts. The company utilizes its proprietary EpiSelect™ platform to identify and develop antibody therapeutics that target toxic oligomers associated with neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD).
Corporate Structure and Team
PROMIS Neurosciences has a small organizational structure, reporting between 2 and 10 employees. Under the leadership of CEO Neil Warma, the company’s scientific team possesses expertise in protein folding, molecular targeting, and neurobiology. According to a Schedule 13G/A filed on May 15, 2025, Armistice Capital, LLC and Steven Boyd collectively hold 2,334,826 shares, which represents 7.14% of the outstanding common stock.
Neurodegenerative Research by Milad Fakurian
Recent Developments and News
On July 26, 2024, PROMIS entered into a private placement financing agreement aimed at raising up to USD 122.7 million. The initial closing provided USD 30.3 million through the sale of common share units and pre-funded units at USD 2.15 and USD 2.14 per unit, respectively. The proceeds are intended to support the Phase Ib study of PMN310 in Alzheimer’s patients. The associated warrants have exercise prices ranging from USD 0.01 to USD 2.50, with certain tranches requiring shareholder approval under Nasdaq Listing Rule 5635(d). This financing closed on July 31, 2024.
In mid-June 2025, the company filed a Current Report on Form 8-K (Items 5.02, 5.07, and 9.01) that disclosed leadership changes and other corporate events. A subsequent 8-K filing on July 7, 2025, provided updates under Item 8.01.
PROMIS initiated dosing of Alzheimer’s disease patients in the Phase 1b PRECISE-AD clinical trial of PMN310 in early 2025. The company anticipates presenting six-month interim data in the first half of 2026, with topline results expected in the second half of 2026.
Financial and Strategic Analysis
| Metric | Data |
|---|---|
| Ticker | PMN |
| Exchange | NASDAQ |
| Share Price (USD) | 0.87 |
| YTD Change (%) | +122.85 |
| Volume | 2,110,387 |
| Average Volume | 594,208 |
| Volume Change (%) | +255.16 |
The USD 30.3 million raised in the July 2024 financing supports the ongoing clinical development of PMN310, PROMIS’s lead therapeutic candidate aimed at targeting toxic amyloid-β oligomers. Full exercise of associated warrants could yield an additional USD 92.4 million, contingent on shareholder approval. Notable institutional healthcare investors in the PIPE included Great Point Partners, Armistice Capital, Ally Bridge Group, and Sphera Healthcare, with Guggenheim Securities acting as the lead placement agent.
Market Position and Industry Context
PROMIS operates within the neurodegenerative disease sector, which includes various monoclonal antibodies targeting amyloid and tau pathologies. The EpiSelect™ engine distinguishes PROMIS by predicting disease-specific conformational epitopes on misfolded proteins, aiming to reduce off-target effects. The company's focus on toxic oligomers rather than plaques or monomers addresses efficacy and safety challenges that have been prevalent with other therapies for Alzheimer’s disease.
As of July 14, 2025, PMN trades on NASDAQ under the ticker symbol PMN, reflecting increased trading activity since the financing and dosing milestones. Management continues to engage investors through events such as the BIO CEO & Investor Conference (New York, May 2025) and the Guggenheim SMID Cap Biotech Conference (February 5, 2025).
tl;dr
PROMIS secured USD 30.3 million (with potential for USD 92.4 million more) in a July 26, 2024 PIPE financing to fund the Phase 1b PMN310 trial. Dosing began in early 2025, with six-month data expected in the first half of 2026 and topline results anticipated in the second half of 2026. Shareholder approval for certain warrants remains pending, and trading volume has increased year-to-date.